Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $626.47M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 1.86M
Average 1.31M
Returns on capital
Alumis Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-80.8%
avg -22.7%
ROIC
-120.2%
avg -141.6%
ROA
-59.1%
avg -105.4%
Analysis
ROA is currently the strongest return metric at -59.1% versus its period average of -105.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Martin Babler | President, Chief Executive Officer & Chairman | USD 1.21M | 61 | 745.88K | 0.60% |
David Goldstein | Chief Scientific Officer | USD 821.19K | 60 | — | — |
Jorn Drappa | Chief Medical Officer & Head of Research and Development | USD 817.06K | 61 | 56.30K | 0.05% |
Roy C. Hardiman | Chief Business & Strategy Officer | USD 619.84K | 66 | 207.09K | 0.17% |
John R. Schroer | Chief Financial Officer | — | 61 | 23.92K | 0.02% |
Mark Bradley | Chief Development Officer | — | 60 | — | — |
Sanam Pangali | Chief Legal Officer & Corporate Secretary | — | 42 | 9.41K | <0.01% |
Kolbot By | Senior Vice President & Head of Technical Operations | — | — | — | — |
Philip Nunn | Senior Vice President of Pharmacology & Project Team Leader | — | — | — | — |
Claire Langrish | Senior Vice President & Head of Immunology and Translational Science | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
32
$56.87M
Sells
15
$1.57M
Net Transaction Value
+$55.30M
Net buying
Most Active
AKKARAJU SRINIVAS
19 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 2, 26Nov 2, 2026 | Hardiman Roy C. Direct | Sell | $4.3K$4,251.04 |
| Nov 2, 26Nov 2, 2026 | Goldstein David M Direct | Sell | $4.1K$4,101.08 |
| Nov 2, 26Nov 2, 2026 | Drappa Jorn Direct | Sell | $3.9K$3,866.36 |
| Nov 2, 26Nov 2, 2026 | Bradley Mark Christopher Direct | Sell | $4.1K$4,061.96 |
| Nov 2, 26Nov 2, 2026 | Pangali Sanam Direct | Sell | $2.2K$2,164.64 |
| Nov 2, 26Nov 2, 2026 | Schroer John R. Direct | Sell | $5.2K$5,176.88 |
| Sep 8, 26Sep 8, 2026 | AKKARAJU SRINIVAS Indirect | Sell | $507K$507,008.85 |
| Sep 8, 26Sep 8, 2026 | AKKARAJU SRINIVAS Indirect | Sell | $507K$507,019.39 |
| Sep 8, 26Sep 8, 2026 | AKKARAJU SRINIVAS Indirect | Buy | $2.9M$2,904,280.16 |
| Sep 8, 26Sep 8, 2026 | AKKARAJU SRINIVAS Indirect | Buy | $2.9M$2,904,290.79 |
1–10 of 47
Summary
Insiders reported 32 buys worth $56.87M and 15 sells worth $1.57M over the last 12 months. That adds up to net buying of $55.30M. AKKARAJU SRINIVAS was the most active insider with 19 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +105.6% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Forward estimates point to Revenue at +105.6% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Alumis Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ALMS's management, answered from reported figures.
Who manages ALMS?
Alumis Inc. Common Stock (ALMS) lists 10 active executives. The top listed executive is Jorn Drappa, Chief Medical Officer & Head of Research and Development.
Are ALMS insiders buying or selling?
Recent insider activity shows net buying of $277.43M.
Continue the stock analysis
Jump to another research area for this company.